Clinical trials: Metastatic Intraocular Melanoma
Metastatic Uveal Melanoma
Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye
The purpose of this study is to see if the combination of entinostat and pembrolizumab can be an effective treatment for patients with melanoma of the eye (uveal melanoma) that has spread to other sites of the body (metastatic…
- Trial name
- PEMDAC (NCT02697630)
- Testing
- Pembrolizumab, Entinostat
- Where
- Sweden
- Volunteers
- 29 people
- Sponsor
- Vastra Gotaland Region
Metastatic Uveal Melanoma
Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)
Because we suspect that the benefit of anti-PD-1 in metastatic UM patients could vary according to previous exposure to Tebentafusp (better efficacy of anti-PD-1 after Tebentafusp), the combination of pembrolizumab and lenvatinib…
- Trial name
- PLUME (NCT05282901)
- Testing
- Pembrolizumab 25 MG/1 ML Intravenous Solution
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Institut Curie
Uveal Melanoma
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
This study seeks to better understand the liver's immune response to receiving chemotherapy agent melphalan through Percutaneous Hepatic Perfusion (PHP) alone or in combination with Ipilimumab and Nivolumab for patients with…
- Trial name
- NCT07364474
- Testing
- Melphalan through Percutaneous Hepatic Perfusion, Melphalan through Percutaneous Hepatic Perfusion in combination with Ipilimumab and Nivolumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
This phase I trial finds out the side effects and possible benefits of stereotactic radiosurgery and immune checkpoint inhibitors with NovoTTF-100M for the treating of melanoma that has spread to the brain (brain metastases).
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
- Trial name
- NCT05341349
- Testing
- Ipilimumab, Nivolumab, Pembrolizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Emory University
Uveal Melanoma
Adjuvant Tebentafusp in High Risk Ocular Melanoma
At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting.
- Trial name
- ATOM (NCT06246149)
- Testing
- Tebentafusp
- Where
- 15 sites in United States, Belgium and 7 more
- Volunteers
- 290 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Intraocular Melanoma
Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01217398
- Testing
- bevacizumab, temozolomide, polymorphism analysis
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Institut Curie
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma
Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases
The purpose of this study is to evaluate the feasibility, safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion in patients with liver metastases…
- Trial name
- HAITILS (NCT04812470)
- Testing
- Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2
- Where
- Sweden
- Volunteers
- 8 people
- Sponsor
- Vastra Gotaland Region
Intraocular Melanoma, Melanoma (Skin)
PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Biological therapies, such as thalidomide, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00238329
- Testing
- PEG-interferon alfa-2b, thalidomide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Uveal Melanoma, Metastatic Cancer
Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma
Phase II clinical trial aimed to evaluate the efficacy of the combination of cediranib and durvalumab in patients with metastatic uveal melanoma (mUM) with biopsiable disease at first line of after failure to first line systemic…
- Trial name
- CEDUVEAL-M (NCT04184518)
- Testing
- Cediranib Maleate, Durvalumab
- Where
- 5 sites in Spain
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
Melanoma, Uveal Metastatic
IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma
A Phase I vaccination trial in patients suffering from recently diagnosed metastatic uveal melanoma not cureable with local therapy and needing systemic therapy.
- Trial name
- NCT04335890
- Testing
- Vaccination with IKKb matured Dendritic Cells
- Where
- Germany
- Volunteers
- 17 people
- Sponsor
- Hasumi International Research Foundation
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Uveal Melanoma
A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma
Uveal melanoma is the most common primary intra-ocular malignancy in adults with an incidence of 0.6 - 0.7 per 100,000 per year. Prognosis of metastatic uveal melanoma is poor.
- Trial name
- STREAM (NCT01377025)
- Testing
- Sorafenib
- Where
- 3 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Prof. Dr. med. Max. E. Scheulen
Uveal Melanoma
A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic…
- Trial name
- NCT02601378
- Testing
- LXS196, LXS196 and HDM201
- Where
- 6 sites in United States, Australia and 4 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Malignant Uveal Melanoma
Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
Marqibo (liposomal vincristine) is a form of vincristine preparation. Vincristine is designed to interfere with the multiplication of cancer cells, which may slow or stop their growing and spreading throughout the body.
- Trial name
- NCT00506142
- Testing
- Marqibo® (vincristine sulfate liposomes injection)
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Uveal Melanoma
Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)
Prospective, open labelled, monocentric trial to evaluation of the circulating tumor DNA rate in the blood, before and after curative resection of hepatic metastasis of uveal melanoma (HMUM) and during post-surgery follow-up
- Trial name
- ctDNA R0 (NCT02849145)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Institut Curie
Melanoma Metastatic, Uveal Melanoma, Metastatic
A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
The goal of this trial is to see if this investigational drug is safe for adult patients with melanoma that has spread to other parts of the body or cannot be removed by surgery.
- Conditions
- Melanoma Metastatic, Uveal Melanoma, Metastatic, Mucosal Melanoma
- Trial name
- NCT07076550
- Testing
- [225Ac]Ac-A9-3408, [68Ga]Ga-A9T-3202
- Where
- 4 sites in Australia
- Volunteers
- 5 people
- Sponsor
- Alpha-9 Oncology USA Inc.
Uveal Melanoma
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)
- Trial name
- NCT07804186
- Testing
- Darovasertib, Crizotinib (Xalkori)
- Where
- 13 sites in United States, Canada
- Volunteers
- 450 people
- Sponsor
- IDEAYA Biosciences
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
This randomized phase II trial studies temozolomide to see how well it works compared to selumetinib in treating patients with melanoma of the eye that has spread to other places in the body.
- Conditions
- Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Uveal Melanoma
- Trial name
- NCT01143402
- Testing
- Dacarbazine, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 33 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
This randomized phase II trial studies how well sunitinib malate or valproic acid works in preventing high-risk uveal (eye) melanoma from spreading to other parts of the body.
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Stage I Intraocular Melanoma
- Trial name
- NCT02068586
- Testing
- Sunitinib, Valproic Acid, Sunitinib Malate
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University